Psoriasis

Psoriasis, like many other conditions of the skin, often has a degree of stigmatization, both internal and external, that leads to increased stress, depression, anxiety and an exacerbation of physical comorbidities.

In this issue of Healio Psoriatic Disease we focus on stigma experienced by patients with psoriasis.

Patient-reported psoriasis signs and symptoms improvement was significantly better in those treated with deucravacitinib over placebo and apremilast, according to two clinical trials presented at the EADV Congress virtual meeting.

Long-term treatment with tapinarof cream 1% was well tolerated and effective in continuing plaque psoriasis improvement, according to an extension study presented at the EADV Congress virtual meeting.

Patient reported data from two phase 3 trials found roflumilast cream 0.3% significantly reduced itch severity and impact in psoriasis patients, according to a presentation at the EADV Congress virtual meeting.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses what it means to patients to be diagnosed with psoriasis.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses the impact of the COVID-19 pandemic on psoriasis care.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses the future of psoriasis research.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses where topical therapies fit into the psoriasis treatment landscape.

In this video, April W. Armstrong, MD, MPH, professor of dermatology and associate dean at Keck School of Medicine at USC, discusses the current treatment options for psoriasis.